TD Cowen initiated coverage of Cartesian Therapeutics with a rating of Buy

Oppenheimer downgraded Cartesian Therapeutics from Outperform to Perform

Oppenheimer initiated coverage of Cartesian Therapeutics with a rating of Outperform and set a new price target of $50.00

Mizuho initiated coverage of Cartesian Therapeutics with a rating of Buy and set a new price target of $40.00

H.C. Wainwright reiterated coverage of Cartesian Therapeutics with a rating of Buy and set a new price target of $54.00 from $2.00 previously

Leerink Partners initiated coverage of Cartesian Therapeutics with a rating of Outperform and set a new price target of $39.00

FREDERICK, Md., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that updated efficacy and safety data from the Phase 2b trial of Descartes-08 in patients with generalized myasthenia gravis will be presented at the 2nd Annual Cell Therapy for Autoimmune Disease Summit, being held December 2-4, 2024 in Philadelphia. Details of the presentation are as follows: Title: Perspectives on Bringing Cell Therapies to the Autoimmune Space: From Concept to ClinicSession Name: Diving into Challenges & Successes in the Autoimmune Space to Direct Futu

Trial met primary endpoint with statistical significance, with 71% of myasthenia gravis patients treated with Descartes-08 observed to have a clinically meaningful improvement in MGC score at Month 3 compared to 25% for placebo Deep and durable responses up to at least six months observed in patients treated with Descartes-08 Safety profile continues to support outpatient administration Company expects to hold End-of-Phase 2 meeting with the FDA by year-end Company to host conference call today at 8:00 a.m. ET GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) ("Cartesian" or the "Company"), a clinical-stage biotechnology company pioneerin

FREDERICK, Md., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that updated efficacy and safety data from the Phase 2b trial of Descartes-08 in patients with generalized myasthenia gravis will be presented at the 2nd Annual Cell Therapy for Autoimmune Disease Summit, being held December 2-4, 2024 in Philadelphia. Details of the presentation are as follows: Title: Perspectives on Bringing Cell Therapies to the Autoimmune Space: From Concept to ClinicSession Name: Diving into Challenges & Successes in the Autoimmune Space to Direct Futu

FREDERICK, Md., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to two new employees. On November 4, 2024, the Company issued to these employees options to purchase an aggregate of 4,854 shares of the Company's common stock with an exercise price of $19.11, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and we

Company expects to commence Phase 3 trial of Descartes-08 in patients with myasthenia gravis in 1H2025 following recent meeting with U.S. Food and Drug Administration Presentation of updated efficacy and safety data from Phase 2b trial and Phase 3 trial design of Descartes-08 in patients with myasthenia gravis expected by year-end Dosing underway in Phase 2 trial of Descartes-08 in patients with systemic lupus erythematosus Dosing underway in first-in-human Phase 1 trial of Descartes-15 Approximately $220.9M of cash, cash equivalents, and restricted cash as of September 30, 2024 expected to support planned operations, including completion of planned Phase

FREDERICK, Md., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that safety and tolerability data from patients treated with Descartes-08 will be featured during a poster presentation at the upcoming 66th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 7-10, 2024 in San Diego. A copy of the abstract is available on the ASH website at www.hematology.org.  Descartes-08, Cartesian's lead mRNA cell therapy candidate, is an autologous mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T

GAITHERSBURG, Md., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to five new employees. On October 1, 2024, the Company issued to these employees options to purchase an aggregate of 60,961 shares of the Company's common stock with an exercise price of $17.11, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan an

GAITHERSBURG, Md., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to Descartes-08 for the treatment of juvenile dermatomyositis (JDM). Descartes-08, Cartesian's lead mRNA cell therapy candidate, is an autologous mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T) product candidate targeting B-cell maturation antigen (BCMA). Descartes-08 is designed to be administered without preconditioning chemotherapy and does not use

GAITHERSBURG, Md., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of an inducement award to a new employee. On September 3, 2024, the Company issued to this employee an option to purchase 3,864 shares of the Company's common stock with an exercise price of $13.12, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The option was granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and was approved by

Descartes-15 observed to achieve an approximately ten-fold increase relative to Descartes-08 in CAR expression and selective target-specific killing in preclinical studies GAITHERSBURG, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that the first patient has been dosed in its first-in-human Phase 1 trial of Descartes-15, the Company's next-generation autologous anti-B cell maturation antigen (BCMA) mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T). "Advancement of Descartes-15 into the clinic marks an import

GAITHERSBURG, Md., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that its management expects to participate in the following investor conferences in September: A fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference at 2:30 p.m. ET on Monday, September 9, 2024 in New York, NYA fireside chat at the Cantor Global Healthcare Conference at 9:45 a.m. ET on Tuesday, September 17, 2024 in New York, NY A live webcast of the fireside chats are expected to be accessible in the Events section of the Company's website at

Presented positive topline results from Phase 2b trial of Descartes-08 in patients with myasthenia gravis; End-of-Phase 2 meeting with FDA expected by year-end Dosed first SLE patient in Phase 2 trial of Descartes-08 IND filing for pediatric basket study of Descartes-08 with focus in neurology and rheumatology expected by year-end PIPE financing strengthened balance sheet, with net proceeds expected to support development of Descartes-08 in MG through planned Phase 3 trial GAITHERSBURG, Md., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today rep

Needham analyst Gil Blum reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $42 price target.

Shares of NIO Inc. (NYSE:NIO) fell sharply during Friday's session after the company disclosed that Steven Wei Feng has resigned as the Chief Financial Officer for personal and family reasons, effective July 5, 2024. NIO shares dipped 8.5% to $4.4550 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Qualigen Therapeutics, Inc. (NASDAQ:QLGN) jumped 120% to $0.3870 after gaining 6% on Wednesday. Zapp Electric Vehicles Group Limited (NASDAQ:ZAPP) rose 70.5% to $4.65 after gaining around 14% on Wednesday. MediWound Ltd. (NASDAQ:MDWD) shares jumped 45.6% to $21.12 after dipping around 7% on Wednesday. Koss Corporation (NASDAQ:KOSS) shares climb

HC Wainwright & Co. analyst Mitchell Kapoor maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and lowers the price target from $54 to $49.

Canaccord Genuity analyst John Newman maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and raises the price target from $38 to $43.

Oppenheimer analyst Matthew Biegler downgrades Cartesian Therapeutics (NASDAQ:RNAC) from Outperform to Peer Perform.

Tuesday, Cartesian Therapeutics Inc (NASDAQ:RNAC) announced topline results from its Phase 2b trial of Descartes-08 in patients with generalized myasthenia gravis (MG). Descartes-08, Cartesian’s lead product candidate, is an autologous mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T) directed against the B cell maturation antigen. It is designed to be administered as an outpatient treatment without requiring lymphodepleting chemotherapy to achieve activity with conventional CAR-T cell therapies. The trial achieved its primary endpoint with statistical significance in the pre-specified mITT efficacy population, with 71% (10/14) of patients treated with Descartes-

Pursuant to the terms of the securities purchase agreement, the Company is selling an aggregate of 3,563,247 shares of its common stock, and 2,937,903 shares of its Series B Non-Voting Convertible Preferred Stock, each at a purchase price of $20.00 per share. Each share of Series B Preferred Stock is convertible into one share of Common Stock, subject to Cartesian stockholder approval thereof and certain beneficial ownership limitations set by the purchasers of the Series B Preferred Stock.

Trial met primary endpoint with statistical significance, with 71% of myasthenia gravis patients treated with Descartes-08 observed to have a clinically meaningful improvement in MGC score at Month 3 compared to 25% for placebo. Deep and durable responses up to at least six months observed in patients treated with Descartes-08. Safety profile continues to support outpatient administration. Company expects to hold End-of-Phase 2 meeting with the FDA by year-end.

SC 13D/A - Cartesian Therapeutics, Inc. (0001453687) (Subject)

SC 13D/A - Cartesian Therapeutics, Inc. (0001453687) (Subject)

SC 13D/A - Cartesian Therapeutics, Inc. (0001453687) (Subject)

SC 13D/A - Cartesian Therapeutics, Inc. (0001453687) (Subject)

SC 13G - Cartesian Therapeutics, Inc. (0001453687) (Subject)

SC 13G/A - Cartesian Therapeutics, Inc. (0001453687) (Subject)

SC 13D/A - Cartesian Therapeutics, Inc. (0001453687) (Subject)

SC 13G/A - Cartesian Therapeutics, Inc. (0001453687) (Subject)

SC 13D/A - Cartesian Therapeutics, Inc. (0001453687) (Subject)

SC 13D/A - Cartesian Therapeutics, Inc. (0001453687) (Subject)

4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)